A traditional Chinese medicine for treating myasthenia gravis and its producing method

Abstract

Disclosed is a Chinese medicament for treating myasthenia gravis, which is prepared from astragalus root 50-60g, wolfberry fruit 15-20g, fleece-flower root 15-20g, white atractylodes rhizome 15-20g, bitter orange 15-20g and cimicifuga rhizome 10-12g.

Description

technical field [0001] The invention relates to a traditional Chinese medicine, in particular to a Chinese patent medicine for treating myasthenia gravis and a production method of the medicine. Background technique [0002] Myasthenia gravis (MG) is a disease characterized by unilateral or bilateral eyelid drooping, limb weakness, morning lightness and evening severity, progressive aggravation or accompanied by dysphagia and unclear articulation. It belongs to different diseases of traditional Chinese medicine, such as MG, which is mainly characterized by weakness of limbs, is equivalent to the atrophy syndrome of traditional Chinese medicine. Eyelid waste is characterized by drooping eyelids. Decreased voice and unclear articulation are mainly characterized by hoarseness and so on. These all belong to the category of flaccid syndrome in the broad sense of TCM. [0003] Myasthenia gravis is one of the refractory diseases of the nervous system. Except for rescuing myasthe...

AI Technical Summary

Problems solved by technology

Because the currently commonly used cholinesterase inhibitors, hormone drugs, and immunosuppressants not only have strong side effects and liver and kidney toxicity, but are also prone to rebound; surgical treatment of thymus removal has a small scope of application, and postoperative risk Increased chances of symptoms; immunoglobulin therapy and plasma exchange therapy are expensive and difficult to promote; bone marrow transplantation is still in the experimental stage for the treatment of myasthenia gravis, and the cost is higher